In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
Future Oncol
; 20(3): 131-143, 2024 Jan.
Article
in En
| MEDLINE
| ID: mdl-37807952
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Multiple Myeloma
Type of study:
Diagnostic_studies
Limits:
Humans
Language:
En
Journal:
Future Oncol
Year:
2024
Document type:
Article
Affiliation country:
Estados Unidos